Lerodalcibep not checked
LIB Therapeutics LLC · LIB003
FollowEvery change as it happens, and a Monday email
Trials
2 active
11 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Familial Hypercholesterolemia - Heterozygous, Heterozygous Familial Hypercholesterolemia (HeFH)
- Main trialPhase 3
- “The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins. The main question\[s\] it aims to answer are: How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety…”In the company’s words, NCT07102511 on ClinicalTrials.gov
- Other names
- LIB003
Other drugs for Familial Hypercholesterolemia - Heterozygous
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- EnlicitideMerck & Co. · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
Coming up2
- 31 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Enrolling by invitation | 31 Jul 2028 | Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH | |
| Phase 3Not yet recruiting | 31 Jul 2031 | Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia | |
| Phase 3Completed | 30 Jun 2022 | Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product | |
| Phase 3Completed | 12 Sep 2022 | Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH | |
| Phase 3Completed | 30 Sep 2022 | Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients | |
| Phase 3Completed | 30 Jul 2023 | Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction | |
| Phase 3Unknown | 15 Nov 2023 | Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction | |
| Phase 3Unknown | 15 Nov 2023 | Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction | |
| Phase 3Completed | 30 May 2024 | Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients | |
| Phase 3Unknown | 30 Jul 2025 | Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction | |
| Phase 2Completed | 7 Apr 2020 | Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026